Alumis Inc. Common Stock – NASDAQ:ALMS
Alumis Inc. Common Stock stock price today
$4.77
-3.29
-40.82%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 15 hours
Alumis Inc. Common Stock stock price monthly change
-27.32%
month
Alumis Inc. Common Stock stock price quarterly change
-27.32%
quarter
Alumis Inc. Common Stock key metrics
Market Cap | 467.35M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlumis Inc. Common Stock stock price history
Alumis Inc. Common Stock stock forecast
Alumis Inc. Common Stock financial statements
Average Price Target
$27.5
Potential upside: 476.51%
Analysts Price target
Financials & Ratios estimates
| 2023 | 0 | -154.99M |
|---|
| 2023 | 89612000 | 53.50M | 59.7% |
|---|
| 2022 | -107.72M | -68.75M | 101.62M |
|---|---|---|---|
| 2023 | -129.97M | 60.47M | 89.68M |
Alumis Inc. Common Stock alternative data
| Jul 2024 | 107 |
|---|---|
| Dec 2024 | 107 |
Alumis Inc. Common Stock other data
-
What's the price of Alumis Inc. Common Stock stock today?
One share of Alumis Inc. Common Stock stock can currently be purchased for approximately $4.77.
-
When is Alumis Inc. Common Stock's next earnings date?
Unfortunately, Alumis Inc. Common Stock's (ALMS) next earnings date is currently unknown.
-
Does Alumis Inc. Common Stock pay dividends?
No, Alumis Inc. Common Stock does not pay dividends.
-
How much money does Alumis Inc. Common Stock make?
Alumis Inc. Common Stock has a market capitalization of 467.35M.
-
What is Alumis Inc. Common Stock's stock symbol?
Alumis Inc. Common Stock is traded on the NASDAQ under the ticker symbol "ALMS".
-
What is Alumis Inc. Common Stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Alumis Inc. Common Stock?
Shares of Alumis Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Alumis Inc. Common Stock have?
As Dec 2024, Alumis Inc. Common Stock employs 107 workers.
-
When Alumis Inc. Common Stock went public?
Alumis Inc. Common Stock is publicly traded company for more then 4 years since IPO on 22 Feb 2021.
-
What is Alumis Inc. Common Stock's official website?
The official website for Alumis Inc. Common Stock is alumis.com.
-
Where are Alumis Inc. Common Stock's headquarters?
Alumis Inc. Common Stock is headquartered at 280 East Grand Avenue, South San Francisco, CA.
-
How can i contact Alumis Inc. Common Stock?
Alumis Inc. Common Stock's mailing address is 280 East Grand Avenue, South San Francisco, CA and company can be reached via phone at +65 02316625.
-
What is Alumis Inc. Common Stock stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Alumis Inc. Common Stock in the last 12 months, the avarage price target is $27.5. The average price target represents a 476.51% change from the last price of $4.77.
Alumis Inc. Common Stock company profile:
Alumis Inc. Common Stock
alumis.comExchange:
NASDAQ
Full time employees:
107
Industry:
Biotechnology
Sector:
Healthcare
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
280 East Grand Avenue
South San Francisco, CA 94080
South San Francisco, CA 94080
:
ISIN: US0223071020
:
